Real-world clinico-genomic evidence can fill knowledge gaps and identify unmet needs for patients with lung cancerRead moreFlatiron Health at WCLC 2025
Flatiron is excited to attend and present our research at the 2025 World Conference on Lung Cancer (WCLC), showcasing how our evidence solutions can be leveraged to generate real-world insights that inform clinical decision-making, reveal treatment gaps, and support innovation across the lung cancer care continuum.
Get a preview of Panoramic Data from Dr. Emily Castellanos, Head of Research Oncology, Clinical Solutions at Flatiron
Flatiron is your trusted partner in delivering oncology evidence to support the evolving research questions across your lung cancer portfolio
500+
published pieces of lung cancer research leveraging Flatiron data
320K+
NSCLC patients with treatment details, biomarkers, pathologic response, recurrence, key outcomes, and more, available at scale
29K+
SCLC patients with brain mets, treatment details, enhanced IVs, key outcomes, adverse events, and more, across the patient journey
10K+
multinational patients with lung cancer from our multi-site network in the UK, Germany, and Japan
9K+
lung cancer patients linked across Flatiron’s best-in-class longitudinal clinical data and Caris’ industry leading molecular data
Featured solutions
Real-world data
Our flexible real-world data (RWD) configurations are tailored to address the specific needs of your lung cancer portfolio and now encompass 4 of the largest oncology markets in the world.
Real-world evidence services
Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your lung cancer portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Flatiron Trials™
We help you design and execute late-phase oncology trials, including interventional trials, with faster and smarter execution powered by our leading application of RWD and AI, comprehensive CRO services, tech-enabled site network, and our suite of clinical research technology.
Our research
Flatiron is excited to share our accepted research at this year’s conference.
Poster presentations
A Novel Predictive Gene Signature for Liver Metastasis (LM) in NSCLC Using a Comprehensive Linked Clinical-Molecular Database
Partner: Caris Life Sciences
This research used the comprehensive linked Flatiron Health-Caris Life Sciences NSCLC Clinical-Molecular Database to identify a novel gene expression signature that can help determine which patients with advanced NSCLC are most at risk for developing liver metastasis.
See this research
Session: P2.06 - Pathology and Biomarkers
Presentation Number: P2.06.45
Location: Exhibit Hall
Session Start/End: Monday, September 8, 10:30AM - 12PM
Presentation Number: P2.06.45
Location: Exhibit Hall
Session Start/End: Monday, September 8, 10:30AM - 12PM
Real-world Biomarker Testing and Treatment Initiation in Patients with Resected Early-stage NSCLC (eNSCLC) in the US and UK
This study examined real-world patterns of EGFR and ALK biomarker testing among over 13,000 US and 100 UK patients with stage IB-IIIA eNSCLC, highlighting ongoing gaps in biomarker testing.
Read more
See this research
Session: P1.07 - Early-Stage Non-small Cell Lung Cancer
Presentation Number: P1.07.05
Location: Exhibit Hall
Session Start/End: September 7, 10:30AM - 12PM
Presentation Number: P1.07.05
Location: Exhibit Hall
Session Start/End: September 7, 10:30AM - 12PM
Real-World Outcomes of Prophylactic Cranial Irradiation (PCI) in Extensive-Stage Small Cell Lung Cancer Treated with First-Line Immunotherapy and Platinum-Etoposide
See this research
Session: P3.13 - Small Cell Lung Cancer and Neuroendocrine Tumors
Presentation Number: P3.13.10
Location: Exhibit Hall
Session Start/End: September 9, 10 - 11:30AM
Presentation Number: P3.13.10
Location: Exhibit Hall
Session Start/End: September 9, 10 - 11:30AM
E-POSTER PRESENTATIONS
Real-World Survival Outcomes in Non–Small Cell Lung Cancer: Insights from UK EHR-Derived Data
This study used a novel dataset derived from the electronic health records of over 2,600 patients in the UK diagnosed with NSCLC between 2016 and 2024 and provides new insights into how NSCLC is managed in the UK.
Read more
Disease Burden and rwPFS as a Surrogate Endpoint for rwOS in NTRK+ NSCLC and Other Advanced/Metastatic Solid Tumors
Partners: Bristol-Myers Squibb, University of Colorado Cancer Center
This study used the Flatiron Health–Foundation Medicine solid tumor and pantumor Clinico-Genomic database to conduct one of the largest real-world studies to date focused on NTRK+ cancers, highlighting the prevalence and incidence of NTRK+ fusions and exploring the relationship between real-world progression-free survival and real-world overall survival.
Real-World Treatment Patterns in ES-SCLC Highlight Continued Unmet Medical Need in the Era of New Therapies: ESSENCE Study
Partners: Montefiore Medical Center, GSK, Rush University
This study used data from the Flatiron Health Panoramic database comprised of >29K patients with SCLC and found that, despite new therapies, many people with ES-SCLC still have few effective options after their cancer returns.
Evolving Treatment Patterns in Early-Stage Non-Small Cell Lung Cancer in the United States
Partners: Lilly
This study used data from the Flatiron Health Panoramic database comprised of >320K patients with NSCLC and found that while the use of traditional platinum-based chemotherapy remained steady, by 2023 about half of patients with stage II/IIIA disease received immunotherapies.
Real-World Treatment Patterns and Clinical Outcomes in Patients With Metastatic Neuroendocrine Neoplasms of the Lung (NEN-L)
Partners: Merck & Co
This research found current real-world treatments strategies for patients with metastatic NEN-L are highly variable and often yield limited benefit, highlighting an urgent unmet need.
Featured content
Ahead of WCLC, discover a selection of our highest impact lung cancer research below.
Real-world clinico-genomic evidence can fill knowledge gaps and identify unmet needs for patients with lung cancerRead more
Want to learn more about how Flatiron’s Evidence Solutions can support research across your lung cancer portfolio?
Leverage Flatiron’s industry-leading oncology solutions to unlock global insights in lung cancer research, including:
-
Real-world data with maximum cohort sizes spanning disease settings from our network of over 320K+ NSCLC and 29K+ SCLC patients
-
9K+ lung patients linked across Flatiron’s best-in-class longitudinal clinical data and Caris’ industry leading molecular data
-
Local real-world data (RWD) cohorts in the US, UK, Germany and Japan
Contact us to learn more about Flatiron’s flexible oncology evidence solutions.